Comparison of 2 Low Molecular Weight Heparin as a Thromboprophylaxis Postpartum
Information source: Hawler Medical University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Venous Thromboembolic Diseases
Intervention: Bemiparin (Drug); Enoxaparin (Drug)
Phase: N/A
Status: Completed
Sponsored by: Hawler Medical University Official(s) and/or principal investigator(s):
Shahla K. Alalaf, Ass.Prof, Principal Investigator, Affiliation: Hawler Medical University
Rojan K. Jawad, High Diploma, Study Chair, Affiliation: Hawler Medical University
Parez R. Muhammad, High Diploma, Study Chair, Affiliation: Hawler Medical University
Mahabad S. Ali, High Diploma, Study Chair, Affiliation: Hawler ministry of Health, Directorate of Health
Namir G. Al Tawil, Professor, Study Director, Affiliation: Hawler Medical University
Summary
The use of a new generation low molecular weight heparin (Bemiparin)and the well known LMWH
(Enoxaparin) after Caesarean sections and vaginal deliveries in a risky group patients for
venous thrombosis.
Clinical Details
Official title: Bemiparin Versus Enoxaparin as Thromboprophylaxis Following Vaginal and Abdominal Deliveries: A Prospective Clinical Trial
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention
Primary outcome: Venous thromboembolism
Secondary outcome: adverse effects
Detailed description:
Venous thromboembolism (VTE) is the leading cause of maternal mortality and morbidity in the
developed and developing world. Pulmonary embolism and deep vein thrombosis are the two
components of a single disease called deep vein thrombosis (DVT). Pregnancy associated with
an average 5 to 10 fold increase in the risk of VTE compared with non-pregnant women. The
highest incidence occurring during the post partum period. There are many researches done a
broad on the effect of LMWH to decrease the incidence of VTE after Caesarean section using
the two LMWH (Enoxaparin and Bemiparin) alone but not in one research comparing both of them
alone and both together against a control group. Also according to our knowledge there are
no published literature on thromboprophylaxis after vaginal delivery
Eligibility
Minimum age: 15 Years.
Maximum age: 48 Years.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- Presence of risk factors for venous thromboembolism
- Any parity
- Mode of delivery: vaginal, Emergency and Elective Caesarean section
- No any contraindications for Heparin
Exclusion Criteria:
- Active antenatal or postpartum vaginal bleeding.
- Placenta previa
- Thrombocytopenia
- Sever renal or liver diseases
- Uncontrolled sever hypertension
- Any patient who is already on Heparin during pregnancy
Locations and Contacts
Hawler medical university, Erbil city, Kurdistan region 383-65, Iraq
Hawler medical university, Erbil, Kurdistan region 383-65, Iraq
Additional Information
Starting date: May 2012
Last updated: March 17, 2015
|
